Localized prostate cancer
|
|
- Robyn Cook
- 5 years ago
- Views:
Transcription
1 Prostate Cancer 2014 Localized prostate cancer Progress toward personalized care Matthew R. Cooperberg, MD,MPH Departments of Urology and Epidemiology & Biostatistics UCSF Mini Medical School July 22, 2014 Siegel et al. CA Cancer J Clin 2014; 64:9 Meet the prostate CaPSURE Disease Registry 1
2 The Changing Face of Prostate Cancer Prostate Cancer Worldwide: 2011 Cooperberg et al. J Urol 2007; 178:S14 Jemal et al. CA Cancer J Clin 2011; 61:69 CaP Risk Among Low SES Men CaP Risk Among Low SES Men CaPSURE CaPSURE SFGH CAPRA Score Porten et al. J Urol 2010; 184:1931 CAPRA Score Porten et al. J Urol 2010; 184:1931 2
3 The good news: So why did we end up here? >40% drop in age-adjusted prostate cancer mortality since early 1990s Siegel et al. CA Cancer J Clin 2013; 63:11 Moyer et al. Ann Intern Med, epub Prostate cancer is heterogeneous This is (partly) our fault. Esserman et al. JAMA 2009; 302:1685 3
4 Treatment options Active surveillance (watchful waiting) Surgery (radical prostatectomy) Radiation (external-beam) Brachytherapy Hormonal therapy Chemotherapy Treatment options (localized) Active surveillance (watchful waiting) Surgery (radical prostatectomy) Open, laparoscopic, robotic Radiation (external-beam) 3DCRT, IMRT, CyberKnife, proton beam, ±hormonal therapy Brachytherapy Permanent vs. HDR, I vs Pd, ±EBRT, ±hormonal tx Hormonal therapy alone Cryotherapy (focal therapy?) (HIFU, interstitial laser, eye-of-newt, etc) Who gets screened? Who gets treated? Walter et al. JAMA 2006; 296:2336 Cooperberg et al. J Clin Oncol 2010; 28:1117 4
5 Older men have worse tumors Treatment driven by age, not risk Bechis et al. J Clin Oncol 2011; 29:235 Bechis et al. J Clin Oncol 2011; 29:235 Treatment Variation Prostate cancer treatment by site Dartmouth Atlas of Health Care, Cooperberg et al. J Clin Oncol 2010; 28:1117 5
6 Recent rays of hope So is the USPSTF right?? PLCO Prostate, Lung, Cancer, & Ovarian Cancer Screening Trial PLCO 76,693 men aged randomly assigned to annual PSA screening for 6 years vs. usual care at 10 U.S. centers the 79% of study men was in the not usual a fair comparison care group between had at screening least one and PSA no test screening; drawn instead, it was a comparison between annual and ad hoc screening. Only Cooperberg 30-40% and of men Carroll, with NEJM high 2009; PSAs had 361:203 biopsies Virtually no difference between types of tumors seen in screening vs. usual care groups Andriole et al. NEJM 2009; 360:1310 Andriole et al. NEJM 2009; 360:1310 6
7 PLCO: Update ERSPC European Randomized Study of Screening for Prostate Cancer PLCO was not a trial of screening vs. no screening Andriole et al. J Natl Cancer Inst 2012; 104:1 Schröder et al. NEJM 2009; 360:1320 ERSPC Population-based study at 7 European centers Number needed to diagnose=33 182,160 men age randomized (162,387 in core age 55-69) Screening interval 4 years at most centers (2 at one) 21% risk reduction for cancer-specific mortality with screening (up to 38% in years 10-11) 29% risk reduction with adjustment for noncompliance Schröder et al. NEJM 2009; 360:1320 The Göteborg randomized trial Göteborg vs. PLCO & ERSPC Younger mean at start of screening Lower PSA threshold for referral Q2 year interval Higher rate of biopsy among those with high PSA Lower rate of PSA contamination Longer followup (though still relatively short) 44% of men were managed with initial surveillance Hugosson J. Lancet Oncol 2010; 11:725 7
8 The Göteborg randomized trial Taking the long view on screening RR 0.56 ( , p=0.002) NNS: 293, NNT: 12 Short-Term Long-Term Lives saved Overdiagnoses A guideline based on outcomes at 8 or 10 years is completely meaningless! Overdiagnoses/Liv es saved 48 7 Hugosson J. Lancet Oncol 2010; 11:725 Gulati et al. J Clin Epidemiol 64:1412, 2011 What about reassurance? Risk Assessment and Risk Adapted Management What seems to be missing from most of the PSA discussion is that the majority of men will have a normal PSA value and they will be reassured A normal PSA level offers peace of mind, a valued commodity in a world that is frequently full of troubling news. Diagnosis Treatment Detsky et al. JAMA 307:1035,
9 Prostate Cancer Risk Assessment Risk Assessment: D Amico / AUA Goal: inform physician-patient decisions about optimal initial treatment approach and timing Active surveillance Early local therapy Multimodal therapy Systemic therapy Low PSA 10, GS 6, and stage T1-2a Intermediate PSA 10-20, GS 7, or stage T2b Numerous existing instruments D Amico Kattan UCSF-CAPRA High PSA >20, GS 8, or stage T2c / T3a D Amico et al. JAMA 1998; 280:969 The UCSF CAPRA The UCSF CAPRA: brfs Variable Level Points Variable Level Points PSA 6 0 T-stage T1/T T3a Gleason (primary/ secondary) % of biopsy <34% 0 cores >30 4 positive >34% 1 1-3/ /4-5 1 Age < /1-5 3 >50 1 Sum points from each variable for 0-10 score Cooperberg et al. J Urol 2005; 173:1938 Cooperberg et al. Cancer 2006; 107:2384 9
10 CAPRA: Cancer specific survival The Myriad Prolaris Assay HR C-index 1.39 ( ) = 0.80 # at risk cell cycle progression (CCP) genes, normalized to 15 housekeeper genes Score is expressed as average centered expression of CCP genes relative to housekeeper genes; negative scores = less active CCP, positive scores = more active CCP Cooperberg et al. JNCI 2009; 101:878 Cuzick J et al. Lancet Oncol 2011; 12:245 Biomarkers vs. clinical parameters 10 year PGP predictions Cooperberg et al, JCO 31:1428, 2013 Cooperberg et al, JCO 31:1428,
11 Oncotype DX Genomic Prostate Score (GPS) Multivariable Performance of GPS Quantitative 17-gene RT- PCR assay on manually microdissected tumor tissue from needle biopsy Genes and biological pathways predictive of multiple endpoints, with emphasis on clinical recurrence Optimized for very small tissue input: six 5 micron sections of single needle biopsy block with as little as 1 mm tumor length Androgen Signaling AZGP1 FAM13C KLK2 SRD5A2 Stromal Response BGN COL1A1 SFRP4 Proliferation TPX2 Cellular Organization FLNC GSN GSTM2 TPM2 Reference ARF1 ATP5E CLTC GPS1 PGK1 GPS = 0.735*Stromal Response group *Androgen Signaling group *Proliferation group *Cellular Organization group Scaled between 0 and 100 Model Variable Odds Ratio 95% CI P-value 1 GPS (per 20 units) 1.85 (1.23, 2.81) Age (continuous) 1.05 (1.01, 1.09) PSA (continuous) 1.11 (1.04, 1.18) Clinical Stage T2 vs. T (0.98, 2.51) Biopsy Gleason Score (7 v. 6) 1.70 (1.00, 2.88) GPS (per 20 units) 2.13 (1.44, 3.16) <0.001 CAPRA 1.58 (1.24, 2.02) <0.001 Cooperberg et al, AUA 2013 Improved Risk Discrimination with Addition of GPS to CAPRA CAPRA 0 = 86% CAPRA 1 = 78% CAPRA 2 = 67% CAPRA 3 = 55% CAPRA 4 = 43% % patients in this range increases from 5% to 24% 49% of pts have 5% change in predicted risk 26% to more favorable 23% to less favorable 5% 5% 36% 38% 16% Cooperberg et al, AUA 2013 GenomeDx and Decipher Decipher is a 22-gene genomic classifier, with genes chosen purely by statistical selection to predict metastasis among high-risk RP patients at Mayo, no pathway analysis (includes noncoding genes, 3 unknowns) Rather than RT-PCR on established gene set, clinical assay is run using Affy Human Exon 1.0ST GeneChip (1.4M probe sets interrogating 5.5M features of whole exome) Decipher score is calculated, but an enormous trove of data is kept in the databank for ongoing / future discovery Erho et al., PLoS ONE 8:e66855,
12 Genomic reclassification But will this change practice? The state of the art isn t bad Will Precision Medicine be enough? 12
13 It s more complicated How do you prove a better decision? 2012 DOD Transformative Impact Award Transforming prostate cancer care (in 3 years) CaPSURE Better Information, Better Understanding, Better Outcomes UCSF Patient Advocates Smoking and PC mortality Watchful wai ng Ac ve surveillance Leveraging models and infrastructure from two industry leaders Stan Rosenfeld John Nidecker UCSF Decision Support Services Active Surveillance to reduce overtreatment 13
14 NIH Consensus Conference Surveillance: Recent Experiences Cooperberg et al. J Clin Oncol 29; 2669: 2011 Active surveillance: challenges Who is eligible? Very low risk only? What about intermediate risk? Is PSA a reliable outcome measure? Is Gleason score a reliable outcome measure? Does upgrading = progression or re-sampling? Interobserver variability What is the role for biomarkers? Can active surveillance be less active? Watchful waiting for IDLE tumors? Outcomes of Surveillance Cooperberg et al. J Clin Oncol 2011; 29:228 14
15 The specter of undersampling Is upgrading trustworthy? N=1097 RP patients at UCSF Percent Toronto Royal Marsden Upgrade ECE SVI Progression vs. undersampling? JHH MSKCC UCSF Conti et al. J Urol 2009; 181: N=17 easy cases: =0.76 ( ) N=17 controversial cases: =0.27 ( ) McKenney et al. J Urol 2011; 186:465 Quantitative Gleason Grading Active Surveillance: Anxiety Treatment decision driven by PSA velocity and anxiety velocity Change nomenclature? PUNLUMP IDLE Reese A et al. Cancer 118:6046, 2012 Latini et al. J Urol 2007; 178:826 15
16 Comparative Effectiveness Research Who should be treated, and how? the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. The purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make informed decisions that will improve health care at both the individual and population levels. Institute of Medicine, 2009 CER: What matters? Cancer control (PSA endpoints, survival) Urinary function (continence vs. irritation) Bowel function Sexual function (potency) PIVOT Trial 52 centers over 7 years screened 13,022 pts to find 5023 eligible and accrue 731 (14.5% of eligible, more likely Af-Am, low grade) Complications blood loss, pain Length of stay, time off work Cost (who pays?) Inappropriate care is never high-quality Wilt T et al. NEJM 2012; 367:203 16
17 PIVOT Trial: low risk PIVOT Trial: high risk Wilt T et al. NEJM 2012; 367:203 Wilt T et al. NEJM 2012; 367:203 Contemporary trials of RP vs. RT RP vs RT BCR definitions are not comparable! (stay tuned for ProtecT) Nielsen et al. Urology 2008; 72:389 17
18 Unadjusted cancer specific survival Results: Cancer specific mortality Predictors of Cancer-Specific Mortality Variable HR p 95% CI Age CAPRA 1.35 < RP Ref EBRT 1.96 < PADT 3.26 < PADT:EBRT HR 1.7 ( ) Cooperberg et al. Cancer 116:5226, 2010 Predicted 15 year cancer specific mortality Results from MSKCC and Baylor 1318 RP and 1062 EBRT patients All EBRT was IMRT 81 Gy Short-course NADT in 56% Predictor for metastasis HR 95% CI P value Age Year of treatment NCCN risk (high vs low/int) <0.001 Surgery vs. EBRT Zelefsky et al. J Clin Oncol 2010; 28:
19 Results from MSKCC and Baylor Zelefsky et al. J Clin Oncol 2010; 28:1508 Quality of life: RP vs. RT? Multiple well-done non-randomized studies (CaPSURE, PROSTQA, Spanish Multicentric Study, PCOS, etc) Specific rates vary, but minimal controversy: Surgery causes more incontinence, but less urinary irritation symptoms (and may improve obstructive symptoms compared to baseline) Radiation causes more irritative symptoms and bowel symptoms Both can cause erection problems surgery has more of an early impact ADT increases QOL impact Open vs. robot assisted surgery? Radiation details De facto nearly all EBRT in the U.S. is now IMRT Increasing the radiation dose improves PSA outcomes; inconsistent findings re: mortality Adding ADT improves outcomes for intermediate- and high-risk disease Brachy likely offers small benefits over IMRT in terms of PSA oucomes and some QOL domains Brachy + EBRT may be better than EBRT alone for high-risk disease, but increases QOL risks 19
20 What about costs? A cost effectiveness model Nguyen et al. J Clin Oncol 2011; 29:1517 Cooperberg et al. BJU Int 2013; 111:437 Results: low risk Results: high risk Proton beam therapy shouldn t even be considered! Cooperberg et al. BJU Int 2013; 111:437 Cooperberg et al. BJU Int 2013; 111:437 20
21 Protons: If you build it they will come We are building it Adjusted OR for receiving proton beam therapy for pts residing in San Bernadino: 5.5 Aaronson et al. Arch Intern Med 172:280, Prostate cancer treatment variation But what if we do listen to the USPSTF? Willet F. Whitmore, Jr 21
22 Conclusions UCSF Urologic Oncology Don t trust the NY Times to interpret complex literature! Screening saves lives, period. But screening must be done better. Coming soon: AQUA Cancer management must be risk-adapted. If diagnosis does not lead inevitably to treatment then overdiagnosis (AUA Quality will be Registry) less of a problem. Decisions should be driven by health and risk, not age. Biomarkers and imaging may help, but we don t need to wait Peter Carroll Katsuto Shinohara Max Meng Kirsten Greene Sima Porten Nannette Perez Janet Cowan Shoujun Zhao Niloufar Ameli June Chan Stacey Kenfield Jenny Broering Jeff Simko Mark Bridge Imelda Tenggara Sarah Joost 22
How will new biomarkers change prostate cancer management
How will new biomarkers change prostate cancer management Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics BAUS Section of Oncology Annual Meeting Cardiff, UK 15 November
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationProstate Cancer: Screening, Treatment, and Survivorship
Prostate Cancer: Screening, Treatment, and Survivorship Timothy C. Brand, MD, FACS LTC(P), MC, USA Urology Residency Director Associate Professor of Surgery, USUHS Madigan Army Medical Center No Disclosures
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationRisk Migration ( ct2c=high)
Risk Migration ( ctc=high) Prostate Cancer Over- Detection, but Selective Treatment Active Surveillance Peter R. Carroll, MD, MPH Department of Urology University of California, San Francisco February,
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationPersonalizing prostate cancer care: A clinical perspective on imaging and other biomarkers in 2017
Personalizing prostate cancer care: A clinical perspective on imaging and other biomarkers in 2017 Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics @dr_coops Osher
More informationPSA-based Early Detection in the US:
PSA-based Early Detection in the US: What Went Wrong, and How to Screen Smarter Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics @dr_coops PAHO/WHO Consultation on
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationActive Surveillance for Intermediate Risk Prostate Cancer
Active Surveillance for Intermediate Risk Prostate Cancer Eric Wallen, M.D., FACS Professor Department of Urology The University of North Carolina at Chapel Hill Disclosures: None Objectives Understand
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More information3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD
PROSTATE CANCER IN 2018 Rahul Mehan, MD East Valley Urology Center 6116 E Arbor Ave, Bldg 2, Suite 108 Mesa, AZ 85206 rmehan@evucenter.com www.evucenter.com Snapchat: Dr.NoodleKing OBJECTIVE Offer interactive
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationA Genomic Approach to Active Surveillance
A Genomic Approach to Active Surveillance Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Cleveland Clinic Disclosures
More information3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014?
3/22/ Goals of this Presentation: in 15 min & 5 min Q & A 1. Potency Preservation. a. Dosimetric considerations Radiotherapy for b. Drugs 2. Update on duration of short term ADT Mack III, MD Professor
More informationPROSTATE CANCER Amit Gupta MD MPH
PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationMultigene Testing in Prostate Cancer Risk Stratification
Multigene Testing in Prostate Cancer Risk Stratification Ashley Ross, MD, PhD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Objectives Briefly review relevant molecular biology of localized
More informationSHARED DECISION MAKING FOR PROSTATE CANCER SCREENING
SHARED DECISION MAKING FOR PROSTATE CANCER SCREENING 16 TH A N N U A L M A S S A C H U S E T T S P R O S T A T E C A N C E R S Y M P O S I U M Mary McNaughton-Collins, MD, MPH Foundation Medical Director
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationProstate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto
Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA
More informationC. Stephen Farmer, II MD Urology Associates
C. Stephen Farmer, II MD Urology Associates Benign Prostate Hypertrophy Benign Prostate Hypertrophy Symptoms Hesitancy Intermittency Nocturia Post-void dribbling Dysuria Urgency Frequency Hematuria Benign
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More informationGenomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.
Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationMolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer
MolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer Noridian Healthcare Solutions, LLC Please Note: This is a Proposed LCD. Proposed LCDs are works in progress
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationPatterns in the Treatment of Intermediate and High Risk Localized Prostate Cancer
Patterns in the Treatment of Intermediate and High Risk Localized Prostate Cancer Jonathan E. Heinlen, M.D. Stephenson Oklahoma Cancer Center University of Oklahoma Health Sciences Center Disclosures I
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationScreening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014
Screening for Prostate Cancer with the Prostate Specific Antigen (PSA) Test: Recommendations 2014 Canadian Task Force on Preventive Health Care October 2014 Putting Prevention into Practice Canadian Task
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationGene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Policy Number: 2.04.111 Last Review: 04/2018 Origination: 04/2014 Next Review: 04/2019 Policy Blue Cross and Blue Shield
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationScreening for Prostate Cancer US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services
More informationAn educational guide from Genomic Health
Active Surveillance or Immediate Treatment? The Oncotype DX Prostate Cancer Assay helps you and your doctor choose with confidence. For more information, visit OncotypeDX.com. An educational guide from
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationStacy Loeb, MD Department of Urology New York University (NY, USA)
Practice-Changing Publications in Prostate Cancer: The Year in Review Stacy Loeb, MD Department of Urology New York University (NY, USA) Acknowledgement AUA Prostate Cancer Update Course William J Catalona,
More informationTreatment of localized prostate cancer in elderly patients
Editorial Treatment of localized prostate cancer in elderly patients Mohammed Haseebuddin, Marc C. Smaldone Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA Correspondence
More informationEffective Health Care Program
Comparative Effectiveness Review Number 146 Effective Health Care Program Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review Executive Summary Background Prostate cancer
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More informationCancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April Ruth Etzioni Fred Hutchinson Cancer Research Center
Cancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April 2018? Ruth Etzioni Fred Hutchinson Cancer Research Center Three thoughts to begin 1. Cancer screening is a good idea in principle Detect
More informationTrends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance
Trends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance Metropolitan Underwriting Discussion Group Annual Meeting January 30, 2017 Prostate Cancer is Common Rudy Giuliani Dx
More informationMP Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
Medical Policy MP 2.04.111 BCBSA Ref. Policy: 2.04.111 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section: Medicine Related Policies 2.04.33 Genetic and Protein Biomarkers for the Diagnosis and
More informationPROSTATE CANCER CONTENT CREATED BY. Learn more at
PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationMr Declan Cahill Consultant Urological Surgeon The Royal Marsden
Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised
More informationPredictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationProstate Cancer Screening. Eric Shreve, MD Bend Urology Associates
Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration
More informationJ Clin Oncol by American Society of Clinical Oncology INTRODUCTION
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Active Surveillance in Younger Men With Prostate Cancer Michael S. Leapman, Janet E. Cowan, Hao G. Nguyen, Katsuto K. Shinohara, Nannette Perez,
More informationDoes RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia
Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Disclosures Advisory Board/honoraria: Varian Advisory Board: Breast
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME NUMBER 20 JULY 10 2011 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance Sima P. Porten, Jared M. Whitson,
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationDate Modified: March 31, Clinical Quality Measures for PQRS
Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More information16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -
Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30
More informationManagement of Common Problems in Men s Health
Management of Common Problems in Men s Health Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine, UCSF April 10, 2015 Declaration of full disclosure: No conflict of interest Summary
More informationThe Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy. Dr. Matt Andrews Supervisor: Dr. David Bowes
The Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy Dr. Matt Andrews Supervisor: Dr. David Bowes Objectives Discuss the evidence for adjuvant radiotherapy (ART) EORTC, SWOG, ARO Current
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationProstate Cancer Innovations in Surgical Strategies Update 2007!
Prostate Cancer Innovations in Surgical Strategies Update 2007! Curtis A. Pettaway, M.D. Professor Department of Urology The University of Texas M. D. Anderson Cancer Center Radical Prostatectomy Pathologic
More informationSommerakademie Munich, June
Active surveillance: Shrinking the grey zone Sommerakademie Munich, June 30 2016 Active surveillance Overview of 20 year history Laurence Klotz, MD, CM Professor of Surgery Sunnybrook Heatlh Sciences Centre
More informationSorveglianza Attiva update
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
More informationSurvival outcomes for men in rural and remote NSW. Trend in prostate cancer incidence and mortality rates in Australia. The prostate cancer conundrum
7/8/20 7/8/20 Using PROMS to better understand prostate cancer outcomes: The NSW Prostate Cancer Care and Outcomes Study David Smith Research Fellow Cancer Research Division Monash Uni, 26 th June 20 Survival
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationOverview. What is Cancer? Prostate Cancer 3/2/2014. Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014
Prostate Cancer Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014 Overview Start with the basics: Definition of cancer Most common cancers in men Prostate, lung, and colon cancers Cancer
More informationAcknowledgments: Maureen Rice, Rachel Warren, Judy Brown, Meghan Kenny, Sharon Peck-Reid, Sarah Connor Gorber
Screening for prostate cancer with prostate specific antigen and treatment of early-stage or screen-detected prostate cancer: a systematic review of the clinical benefits and harms May 2014 Lesley Dunfield
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationThe Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017
The Evolving Role of PSA for Prostate Cancer Adele Marie Caruso, DNP, CRNP Adult Nurse Practitioner Perelman School of Medicine at the University of Pennsylvania November 4, 2017 The Evolving Role of PSA
More informationPCA MORTALITY VS TREATMENTS
PCA MORTALITY VS TREATMENTS Terrence P McGarty White Paper No 145 July, 2017 In a recent NEJM paper the authors argue that there is no material difference between a prostatectomy and just "observation"
More informationProstate Cancer Active Surveillance: Rationale, Outcomes and Future Directions
Prostate Cancer Active Surveillance: Rationale, Outcomes and Future Directions Daniel W. Lin, MD Professor and Chief of Urologic Oncology Bridges Endowed Professorship of Prostate Cancer Research Department
More information